Cayman, MD Anderson In Cancer Drug Pact | Chemical & Engineering News
Volume 93 Issue 38 | p. 21 | Concentrates
Issue Date: September 28, 2015

Cayman, MD Anderson In Cancer Drug Pact

Department: Business
Keywords: inflammation, cancer, academic-industry collaboration
[+]Enlarge
Researchers at MD Anderson’s South Campus labs in Houston.
Credit: MD Anderson
Researchers at MD Anderson’s South Campus labs in Houston.
 
Researchers at MD Anderson’s South Campus labs in Houston.
Credit: MD Anderson

Biochemicals supplier Cayman Chemical is joining with the University of Texas MD Anderson Cancer Center and Fannin Innovation Studio to form ACF Pharmaceuticals, a drug company that will pursue small-molecule inhibitors for inflammation-induced cancers such as melanoma and colon cancer. Under the pact, Cayman will develop molecules that modulate the cyclooxygenase (COX) pathway. MD Anderson will evaluate them, and Fannin, a Houston-based life science commercialization firm, will provide funding and management.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment